Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma.
Zeng L, Xu H, Li SH, Xu SY, Chen K, Qin LJ, Miao L, Wang F, Deng L, Wang FH, Li L, Fu S, Liu N, Wang R, Li YQ, Wang HY.
Zeng L, et al. Among authors: liu n.
J Immunother Cancer. 2023 May;11(5):e005980. doi: 10.1136/jitc-2022-005980.
J Immunother Cancer. 2023.
PMID: 37130627
Free PMC article.